ICD-10-CM Diagnosis Code C25.3 - Malignant neoplasm of pancreatic duct (original) (raw)
ICD List 2025-2026 Edition
- Home
- ICD-10-CM Codes
- C00–D49
- C15-C26
- C25
- 2026 ICD-10-CM Code C25.3
Malignant neoplasm of pancreatic duct
ICD-10-CM Code:
C25.3
ICD-10 Code for:
Malignant neoplasm of pancreatic duct
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Chronic
Code Navigator:
C25.3 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of pancreatic duct. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2025 through September 30, 2026.
The following anatomical sites found in the Table of Neoplasms reference this diagnosis code given the correct histological behavior: Neoplasm, neoplastic pancreas duct (of Santorini) (of Wirsung) or Neoplasm, neoplastic Santorini's duct or Neoplasm, neoplastic Wirsung's duct .
- Code Information
- Approximate Synonyms
- Clinical Classification
- Tabular List of Diseases and Injuries
- Diagnostic Related Groups Mapping
- Convert to ICD-9 Code
- Table of Neoplasms
- Patient Education
- Other Codes Used Similar Conditions
- Code History
The following list of clinical terms are approximate synonyms, alternative descriptions, or common phrases that might be used by patients, healthcare providers, or medical coders to describe the same condition. These synonyms and related diagnosis terms are often used when searching for an ICD-10 code, especially when the exact medical terminology is unclear. Whether you're looking for lay terms, similar diagnosis names, or common language alternatives, this list can help guide you to the correct ICD-10 classification.
- Infiltrating duct carcinoma of pancreas
- Intraductal papillary mucinous neoplasm of pancreas
- Intraductal tubulopapillary malignant neoplasm of pancreas
- Invasive intraductal papillary-mucinous carcinoma of pancreas
- Malignant neoplasm of pancreatic duct
- Pancreatic ductal adenocarcinoma
- Primary adenocarcinoma of pancreas
- Primary adenocarcinoma of pancreatic duct
- Primary infiltrating duct carcinoma of pancreas
- Primary invasive intraductal papillary-mucinous carcinoma of pancreas
- Primary malignant neoplasm of pancreatic duct
- Primary mixed acinar ductal carcinoma of pancreas
- Undifferentiated carcinoma with osteoclast-like giant cells of pancreas
Clinical Classifications group individual ICD-10-CM diagnosis codes into broader, clinically meaningful categories. These categories help simplify complex data by organizing related conditions under common clinical themes.
They are especially useful for data analysis, reporting, and clinical decision-making. Even when diagnosis codes differ, similar conditions can be grouped together based on their clinical relevance. Each category is assigned a unique CCSR code that represents a specific clinical concept, often tied to a body system or medical specialty.
CCSR Code: NEO051
Inpatient Default: Y - Yes, default inpatient assignment for principal diagnosis or first-listed diagnosis.
Outpatient Default: Y - Yes, default outpatient assignment for principal diagnosis or first-listed diagnosis.
Below are the ICD-9 codes that most closely match this ICD-10 code, based on the General Equivalence Mappings (GEMs). This ICD-10 to ICD-9 crosswalk tool is helpful for coders who need to reference legacy diagnosis codes for audits, historical claims, or approximate code comparisons.
ICD-9-CM: 157.3
This is a direct match with no additional mapping qualifiers. The absence of a flag generally means the mapping is considered exact or precise. In other words, the ICD-10 code maps cleanly to the ICD-9 code without qualification, approximation, or needing multiple codes.
This code is referenced in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.
Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.
Filter table of neoplasms:
| Neoplasm, neoplastic | Malignant Primary | Malignant Secondary | CaInSitu | Benign | Uncertain Behavior | Unspecified Behavior |
|---|---|---|---|---|---|---|
| »Neoplasm, neoplastic »pancreas »duct (of Santorini) (of Wirsung) | C25.3 | C78.89 | D01.7 | D13.6 | D37.8 | D49.0 |
| »Neoplasm, neoplastic »Santorini's duct | C25.3 | C78.89 | D01.7 | D13.6 | D37.8 | D49.0 |
| »Neoplasm, neoplastic »Wirsung's duct | C25.3 | C78.89 | D01.7 | D13.6 | D37.8 | D49.0 |
Pancreatic Cancer
The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include:
- Smoking
- Long-term diabetes
- Chronic pancreatitis
- Certain hereditary disorders
Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it.
Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells.
NIH: National Cancer Institute
Pancreatic Cancer-Patient Version
Learn about pancreatic cancer risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]
Pancreatic Cancer Summary
Learn about pancreatic cancer risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]
FY 2026 - No Change, effective from 10/1/2025 through 9/30/2026
FY 2025 - No Change, effective from 10/1/2024 through 9/30/2025
FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.
